- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Metabolic control may improve life expectancy in type 2 diabetes patients: JAMA
USA: Achieving recommended goals is likely to extend the life expectancy (LE) of type 2 diabetes patients, concludes a recent study published in JAMA Network Open.
The researchers suggested the potential profits in life expectancy (LE) affiliated with biomarker improvement, discovering that improving each of the four biomarkers, namely lowering glycated hemoglobin (HbA1c), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), and body mass index (BMI) toward required guidelines, was associated with gains in LE, though the pattern and magnitude varied between them and depending on patients' characteristics.
In the United States, progress in controlling risk factors for diabetes has stopped and remains inadequate. To date, no studies have been conducted to assess the value of constantly increasing target attainment. To estimate prospective increases in LE among persons with type 2 diabetes (T2D) related with HbA1c, SBP, LDL-C, and BMI toward ideal ranges, this study was done.
BRAVO analysis for the diabetes microsimulation model was validated to a nationally representative of adults with T2D from the National Health and Nutrition Examination Survey (2015-2016) utilizing linked short-term mortality data from the National Death Index in this decision analytical model. The model was then utilized to run a simulation experiment on the study population over the course of a lifetime. The data were examined from January to October 2021. The study population was divided into quartiles based on HbA1c, LDL-C, SBP, and BMI values. Moving persons with T2D from the present quartile of each biomarker to the lowest quartiles were used to estimate the LE benefits associated with improved control.
The results assessed tell that using data from 421 persons with T2D, this decision analysis model revealed that those in the lowest BMI, HbA1c, SBP, and LDL-C population quartile had 3.9, 3.8, 1.9, and 0.9 years of extra LE, respectively, compared to those in the highest BMI, HbA1c, SBP, and LDL-C population quartile.
In conclusion, the findings may be utilized by physicians and patients to establish appropriate treatment objectives, motivate patients to achieve them, and quantify possible health benefits for initiatives and programs to enhance diabetes care in the United States.
Reference:
Kianmehr H, Zhang P, Luo J, et al. Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. JAMA Netw Open. 2022;5(4):e227705. doi:10.1001/jamanetworkopen.2022.7705
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751